Open AccessDoxorubicin hydrochloride liposome and albumin-bound paclitaxel in cancer: a nanotechnology perspective
Author(s) -
Rajib Hossain,
Rasel Ahmed Khan,
Muhammad Torequl Islam,
Divya Jain,
Pracheta Janmeda,
Obinna C. Godfrey,
Shiwali Bisht,
Aakanksha Bharati
Publication year - 2021
Publication title -
the applied biology and chemistry journal
Language(s) - English
Resource type - Journals
ISSN - 2582-8789
DOI - 10.52679/tabcj.2021.0010
Subject(s) - doxorubicin hydrochloride , doxorubicin , paclitaxel , cancer cell , liposome , cancer , pharmacology , chemistry , nanomedicine , cancer research , medicine , nanotechnology , chemotherapy , nanoparticle , biochemistry , materials science
Nanoparticles (1-100 nanometres in size), products of nanotechnology, offer a modern way to transport anti-cancer drugs by acting as transporters of drugs into tumor cells, hence quenching tumor cell proliferation. Such nanoparticles may be formulated to bind to the tumor cell membrane or inhibit specific reactions of tumor biosynthetic pathway by gene repression, or directly bind to the active sites of essential enzymes in the biosynthetic pathway. Consequently, drugs are completely delivered to the desired cancerous cells without system interference. Liposomal doxorubicin and albumin-bound paclitaxel are two examples of nanotechnologically developed drugs for treating cancer. Modern knowledge of nanotechnology opens up new opportunities for innovative research on cancer therapies and administration and helps minimize harm to healthy cells. This review focuses on the doses and routes of administration of these chemotherapeutic agents used in treating cancers.